This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Reports CUDC-907 Preliminary Data From The Ongoing Phase 1 Trial At ASH 2013 Annual Meeting

Dose limiting toxicities (DLTs) of Grade 3 diarrhea and Grade 4 hyperglycemia were reported in 1 patient at the 60 mg QD dose. Treatment-related serious adverse events (AEs) of Grade 3 epistaxis (30 mg QD, n=1), and Grade 3 diarrhea and Grade 4 hyperglycemia (60 mg QD, n=1) were also reported with the daily schedule. To date, the most frequent (reported in ≥  2 patients) Grade 3 or 4 AEs include thrombocytopenia, diarrhea and neutropenia, thus far only with the QD administration schedule. Toxicities have limited the ability to further dose escalate using the QD schedule. By contrast, no DLTs or dose interruptions have been reported for patients enrolled onto the BIW regimen at the 60mg dose level. 

Eleven of the 13 patients included in the ASH presentation were evaluable for response assessment per protocol. One of these patients had mixed follicular lymphoma/ diffuse large B cell lymphoma and achieved a PR (70% reduction in a single target lesion) at the 30 mg QD dose level. Seven other patients have met criteria for SD, including 4 with SD lasting at least 4 cycles of treatment. One of these patients (MM) is currently in Cycle 13.

Preliminary pharmacokinetic analysis shows low CUDC-907 plasma levels as compared to its M1 and M2 (PI3K-active) metabolite species. This is consistent with animal studies that demonstrated higher levels of CUDC-907 in tissues as compared to plasma. Additional pharmacokinetic and pharmacodynamic analyses are ongoing.

About CUDC-907

CUDC-907 is a dual inhibitor of Class I and II HDAC as well as Class I PI3K enzymes. Specifically, CUDC-907 is designed to inhibit HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms, the combined inhibition of which Curis believes has synergistic effects against cancer cells and their microenvironment. In preclinical studies, CUDC-907 has demonstrated the ability to suppress multiple nodes of cellular survival and proliferation signaling pathways. In addition, preclinical data have shown that CUDC-907 inhibits compensatory pathways that are often utilized in cancer cells during the emergence of resistance to standard-of-care agents.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs